Heart device tested in Real-World AF patients

NCT ID NCT05434650

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 200 people with persistent atrial fibrillation (AF) who undergo a heart procedure using Abbott's ablation catheter. The catheter uses heat to scar tiny areas in the heart and block faulty electrical signals. Researchers track how many patients stay free of AF for up to 3 years, and check for serious side effects within a week of the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Abbott Ablation Catheter (TactiCath SE) delivering radiofrequency energy
What this could lead to
If successful, this could confirm that the ablation device is a safe and effective long-term option for controlling atrial fibrillation without needing lifelong medication.
What could go wrong
This is a post-approval study, not a new breakthrough. The procedure carries risks like heart damage, stroke, or bleeding. Success depends on patient selection and real-world conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL ARRHYTHMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Arkansas Cardiology

    Little Rock, Arkansas, 72205, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Brigham & Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Centennial Medical Center

    Nashville, Tennessee, 37203, United States

  • Chippenham Hospital

    Richmond, Virginia, 23225, United States

  • Doylestown Hospital

    Doylestown, Pennsylvania, 18901, United States

  • Eisenhower Medical Center

    Rancho Mirage, California, 92270, United States

  • Erlanger Medical Center

    Chattanooga, Tennessee, 37403, United States

  • Heart Center Research, LLC.

    Huntsville, Alabama, 35801, United States

  • Methodist Hospital of San Antonio

    San Antonio, Texas, 78229, United States

  • North Mississippi Medical Center

    Tupelo, Mississippi, 38801, United States

  • Northside Hospital

    Atlanta, Georgia, 30342, United States

  • Ochsner Medical Center

    New Orleans, Louisiana, 70121, United States

  • Oklahoma Heart Hospital South

    Oklahoma City, Oklahoma, 73135, United States

  • Providence Hospital

    Southfield, Michigan, 48075, United States

  • Sentara Norfolk General Hospital

    Norfolk, Virginia, 23507, United States

  • Sequoia Hospital

    Redwood City, California, 94062, United States

  • St. Marks Hospital

    Salt Lake City, Utah, 84124, United States

  • St. Patrick Hospital

    Missoula, Montana, 59802, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.